Enabling Ciprofloxacin Resistance-Guided Therapy for Neisseria gonorrhoeae : Aligning Diagnostics, Regulation, Guidelines, and Reimbursement
Year: 2026
Type: article
Abstract: Gonorrhea treatment in the United States relies on empirically administered intramuscular ceftriaxone. Diagnostics to predict Neisseria gonorrhoeae ciprofloxacin susceptibility/resistance could enable use of ciprofloxacin, a low-cost, single-dose oral antibiotic, to treat ciprofloxacin-susceptible gonorrhea. Ciprofloxacin resistance in N. gonorrhoeae is overwhelmingly mediated by a single mutation in gyrA at codon 91. Molecular interrogation of this site reliably predicts ciprofloxacin resistance and susceptibility. The Antibacterial Resistance Leadership Group (ARLG) is performing a multicenter, multicompany study to generate regulatory-grade clinical performance data to support Food and Drug Administration submissions of multiple nucleic acid amplification tests to predict ciprofloxacin susceptibility in N. gonorrhoeae. In December 2025, a multidisciplinary group was convened by the ARLG and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator to discuss a coordinated pathway to enable individualized ciprofloxacin resistance-guided gonorrhea therapy in the United States, acknowledging this will require integration across diagnostics, regulation, guidelines, reimbursement, and implementation. Meeting highlights are presented.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciag640
Authors: Betsy Wonderly Trainor, Jennifer L Osborn, Jeffrey D Klausner, Michael J Satlin, Sarah N Buss, Alicia Scheffer-Wong, Annette Harris, Barbara Van Der Pol, Carolyn Deal, Ashley Nenninger, Elisa Mokany, Kyung Moon, Joseph D Yao, Lindley A Barbee, Yonatan H Grad, Richard Alm, Lao-Tzu Allan-Blitz, Deborah Godes, Elizabeth M Marlowe, Scott R Evans, Lauren Komarow, Stephanie E McLaughlin, Brooke E Nichols, Robin Patel
Institutions: Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, University of Southern California, Weill Cornell Medicine, Association of Public Health Laboratories, University of Alabama at Birmingham, UAB Medicine, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Mayo Clinic, Centers for Disease Control and Prevention, National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention, Harvard University, University of California, Los Angeles, George Washington University, University of Washington, Boston University
Language: English
Subfield: Microbiology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,763
OpenAlex ID: W7223249696
